← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Hdt Bio Corporation
Seattle, WA
$24,772,935
Total funding
17
Grants
Funding over time
peak $6.2M · FY2018–25$10M$7.5M$5M$2.5M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$24,247,967 · 15
CDC$524,968 · 2
By mechanism
N01$12,991,328 · 4
R61$4,545,890 · 2
R01$2,165,308 · 1
R43$2,020,489 · 7
R33$1,963,600 · 1
N43$599,629 · 1
Investigators at Hdt Bio Corporation
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Development of a COVID-19 Vaccine$4,236,540
N01 · FY2020 · AI
Development of a COVID-19 Vaccine$4,015,904
N01 · FY2021 · AI
Development of a COVID-19 Vaccine$2,717,614
N01 · FY2022 · AI
THERAPEUTICS FOR EMERGING HUMAN ENTEROVIRUSES$1,499,422
N01 · FY2022 · AI
Immunological mechanism of muscle-localizing self-replicating RNA vaccines$1,090,789
R01 · FY2025 · AI
Immunological mechanism of muscle-localizing self-replicating RNA vaccines$1,074,519
R01 · FY2024 · AI
Engineering the Immune Response of a Self-replicating and Adjuvanting RNA HIV-1Vaccine$1,046,474
R61 · FY2022 · AI
Engineering the Immune Response of a Self-replicating and Adjuvanting RNA HIV-1Vaccine$981,917
R33 · FY2024 · AI
Engineering the Immune Response of a Self-replicating and Adjuvanting RNA HIV-1Vaccine$981,683
R33 · FY2025 · AI
Engineering the Immune Response of a Self-replicating and Adjuvanting RNA HIV-1Vaccine$940,253
R61 · FY2023 · AI
Engineering the Immune Response of a Self-replicating and Adjuvanting RNA HIV-1Vaccine$927,069
R61 · FY2021 · AI
RATIONAL DEVELOPMENT OF A COMBINATION NANOPARTICLE ADJUVANT FOR INFLUENZA.$599,629
N43 · FY2019 · AI
RNA Vaccine Innovations for TB: Targeting the Mucosa$550,719
R61 · FY2022 · AI
RNA Vaccine Innovations for TB: Targeting the Mucosa$543,301
R61 · FY2024 · AI
RNA Vaccine Innovations for TB: Targeting the Mucosa$538,074
R61 · FY2023 · AI
Targeting and Imaging Ovarian Cancer with Junction Opener Conjugated-Lipid Iron Oxide Nanoparticles (JOC-LIONs)$399,285
R43 · FY2021 · CA
PA21259, SBIR Phase I, Developing a RIG-I agonist to prevent COVID-19$299,984
R43 · FY2022 · IP
Development of an adaptable RNA vaccine against enterovirus D68 infection for the prevention of acute flaccid myelitis$299,976
R43 · FY2021 · AI
Antibody Therapy for Enterovirus EV-D68 Infection$299,959
N01 · FY2020 · AI
Development of a RIG-I agonist RNA as a cure for chronic Hepatitis B$275,211
R43 · FY2023 · AI